AMED Amedisys Inc.

Media Statement from Amedisys Commending the Home Health Payment Innovation Act

Media Statement from Amedisys Commending the Home Health Payment Innovation Act

BATON ROUGE, La., Feb. 13, 2019 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), America’s leading independent home health, hospice and personal care company, commends bipartisan legislation to preserve and expand home health to those who need it the most.

“Monday, our congressional champions introduced S. 433 – The Home Health Payment Innovation Act, once again showing support for home health and the value it provides to Medicare beneficiaries,” stated Amedisys President and CEO Paul Kusserow. “We look forward to seeing this policy advance so that aging Americans can continue to live independently at home.”

The bipartisan bill, introduced in Congress on Monday night, would not only preserve but also expand access for millions of Medicare beneficiaries to vitally needed health care services that are delivered to the home. This legislation, when enacted, would ensure that rate cuts due to take effect under the Patient Driven Groupings Model (PDGM) in 2020 are based on observed evidence, prohibiting CMS from making behavioral assumptions regarding home health responses to the new payment model.

Amedisys appreciates the leadership of Senator Susan Collins (R-ME), Senator Debbie Stabenow (D-MI), Senator John Kennedy (R-LA), Senator Bill Cassidy (R-LA), Senator Rand Paul (R-KY), Doug Jones (D-AL) and Jeanne Shaheen (D-NH) on this important policy. We have been working with these members and their staffs for over a year on this policy and look forward to continuing our work with these leaders, and all the members of Congress, to advance this important policy. We continue our work with House members and staff and look forward to an introduction of a companion bill very soon in the House of Representatives.

About Amedisys:

Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 3,000 hospitals and 65,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With more than 21,000 employees in 472 care centers in 38 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 376,000 patients and clients in need every year. For more information about the Company, please visit: .

Kendra Kimmons
Vice President of Marketing & Communications
225-299-3708
EN
13/02/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amedisys Inc.

 PRESS RELEASE

Amedisys Reports Second Quarter 2025 Financial Results

Amedisys Reports Second Quarter 2025 Financial Results BATON ROUGE, La., July 29, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2025. Three-Month Periods Ended June 30, 2025 and 2024 Net service revenue increased $30.7 million to $621.9 million compared to $591.2 million in 2024.Net income attributable to Amedisys, Inc. of $28.1 million, which is inclusive of merger-related expenses totaling $26.3 million ($26.1 million, net of tax), compared to net income attributable to Amedisys, ...

 PRESS RELEASE

Amedisys Reports First Quarter 2025 Financial Results

Amedisys Reports First Quarter 2025 Financial Results BATON ROUGE, La., April 23, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2025. Three-Month Periods Ended March 31, 2025 and 2024 Net service revenue increased $23.4 million to $594.8 million compared to $571.4 million in 2024.Net income attributable to Amedisys, Inc. of $61.0 million, which is inclusive of merger-related expenses totaling $16.8 million ($16.6 million, net of tax) and a $48.1 million gain on an equity method investment ($35.6 mi...

 PRESS RELEASE

Amedisys Reports Fourth Quarter and Year End 2024 Financial Results

Amedisys Reports Fourth Quarter and Year End 2024 Financial Results BATON ROUGE, La., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2024. Three-Month Periods Ended December 31, 2024 and 2023 Net service revenue increased $27.3 million to $598.1 million compared to $570.8 million in 2023.Net loss attributable to Amedisys, Inc. of $20.4 million, which is inclusive of merger-related expenses totaling $17.4 million ($15.9 million, net of tax) and a non-cash goodwill and other inta...

 PRESS RELEASE

Amedisys Honors 47 Employees With Annual Spirit of Excellence Award

Amedisys Honors 47 Employees With Annual Spirit of Excellence Award BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the prestigious Spirit of Excellence Awards, one of the company’s highest honors. “Every day, our employees bring warmth, compassion and clinical expertise into the homes of our patients, offering the care they need in the place they most want to be,” said Richard Ashworth, President and Chief Executive Officer. “We are privileged to ...

 PRESS RELEASE

Amedisys Reports Third Quarter 2024 Financial Results

Amedisys Reports Third Quarter 2024 Financial Results BATON ROUGE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2024. Three-Month Periods Ended September 30, 2024 and 2023 Net service revenue increased $31.5 million to $587.7 million compared to $556.2 million in 2023.Net income attributable to Amedisys, Inc. of $16.9 million, which is inclusive of merger-related expenses totaling $16.7 million ($16.7 million, net of tax) compared to net income attributable...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch